Nanoparticles hold great promise for the treatment of glioblastoma by targeting hypoxia and enhancing immune responses. However, following intravenous administration, the amount of nanoparticles reaching the tumor remains limited. Here, we propose grafting moieties that specifically recognize proteins overexpressed in the glioblastoma vasculature and on the surface of immunosuppressive macrophages.